Bangkok, Aug 5 (TNA) – The Chulabhorn Royal Academy (CRA) and the Faculty of Pharmaceutical Science at Chulalongkorn University introduced Thailand’s first favipiravir syrup for COVID-infected children and patients with swallowing difficulty.
CRA secretary-general Prof Dr Nithi Mahanonda said that during the present wave of COVID-19, 10% of patients were children and to survive they would need antiviral drug favipiravir within four days after developing severe symptoms.
According to him, Chulabhorn Hospital is capable of producing and distributing favipiravir syrup to about 300 patients per week. CRA is ready to share the formula of the syrup with any hospitals that are capable of producing it with quality control.
Medical personnel and hospitals can seek the syrup via www.favipiravir.cra.ac.th. (TNA)
